menu
    • menu
    [{"orgOrder":0,"company":"Moleac","sponsor":"National University Hospital Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MLC901","moa":"Cholinesterase","graph1":"Neurology","graph2":"Phase II","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Moleac \/ National University Hospital Singapore","highestDevelopmentStatusID":"8","companyTruncated":"Moleac \/ National University Hospital Singapore"},{"orgOrder":0,"company":"Moleac","sponsor":"PT Ferron Par Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"MLC901","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Moleac \/ PT Ferron Par Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Moleac \/ PT Ferron Par Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Moleac

    Menu

    Moleac

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Moleac

                            Singapore arrow
                            Fi Europe 2024
                            Not Confirmed

                            Moleac

                            Singapore arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MLC901

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : PT Ferron Par Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Moleac Announces PT Ferron Par Pharmaceuticals As New Exclusive Partner in Indonesia

                            Details : Under the partnership, PT Ferron Par Pharmaceuticals will become Moleac's exclusive partner in Indonesia of NeuroAiD II MLC901 which consists of extracts from 9 herbal components.

                            Brand Name : NeuroAiD II

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 21, 2024

                            Lead Product(s) : MLC901

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : PT Ferron Par Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Moleac

                            Singapore arrow
                            Fi Europe 2024
                            Not Confirmed

                            Moleac

                            Singapore arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MLC901

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : National University Hospital Singapore

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NeuroAiD(TM)II Holds Promise as a Safe Add-on Therapy to Standard Alzheimer Disease Symptomatic Treatments and...

                            Details : ATHENE study results support the benefit of NeuroAiD™II (MLC901) as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.

                            Brand Name : NeuroAiD II

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 21, 2022

                            Lead Product(s) : MLC901

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : National University Hospital Singapore

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth